Synonym
AEG40730 HCl; AEG40730 dihydrochloride; AEG40730; AEG-40730; AEG 40730;
IUPAC/Chemical Name
(2S,2'S)-N,N'-((2S,2'S,3R,3'R)-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(1-oxo-1-((S)-2-((2,2,2-trifluoro-N-phenethylacetamido)methyl)pyrrolidin-1-yl)butane-3,2-diyl))bis(2-(methylamino)propanamide) dihydrochloride
InChi Key
CDGBXBVDDLOZGF-CLHBFWEXSA-N
InChi Code
InChI=1S/C52H68F6N8O8.2ClH/c1-35(59-5)45(67)61-43(47(69)65-27-17-23-41(65)33-63(49(71)51(53,54)55)29-25-39-19-11-9-12-20-39)37(3)73-31-15-7-8-16-32-74-38(4)44(62-46(68)36(2)60-6)48(70)66-28-18-24-42(66)34-64(50(72)52(56,57)58)30-26-40-21-13-10-14-22-40;;/h9-14,19-22,35-38,41-44,59-60H,17-18,23-34H2,1-6H3,(H,61,67)(H,62,68);2*1H/t35-,36-,37+,38+,41-,42-,43-,44-;;/m0../s1
SMILES Code
O=C(C(F)(F)F)N(CCC1=CC=CC=C1)C[C@H]2N(CCC2)C([C@@H](NC([C@@H](NC)C)=O)[C@@H](C)OCC#CC#CCO[C@@H]([C@H](NC([C@@H](NC)C)=O)C(N3[C@@H](CCC3)CN(C(C(F)(F)F)=O)CCC4=CC=CC=C4)=O)C)=O.[H]Cl.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,120.07
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Faye MD, Beug ST, Graber TE, Earl N, Xiang X, Wild B, Langlois S, Michaud J, Cowan KN, Korneluk RG, Holcik M. IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene. 2015 Mar 19;34(12):1532-41. doi: 10.1038/onc.2014.90. Epub 2014 Apr 7. PMID: 24704827.
2: Cheung HH, Beug ST, St Jean M, Brewster A, Kelly NL, Wang S, Korneluk RG. Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. J Biol Chem. 2010 Dec 24;285(52):40612-23. doi: 10.1074/jbc.M110.183616. Epub 2010 Oct 18. PMID: 20956527; PMCID: PMC3003360.
3: Cheung HH, Mahoney DJ, Lacasse EC, Korneluk RG. Down-regulation of c-FLIP Enhances death of cancer cells by smac mimetic compound. Cancer Res. 2009 Oct 1;69(19):7729-38. doi: 10.1158/0008-5472.CAN-09-1794. Epub 2009 Sep 22. PMID: 19773432.
4: Galbán S, Hwang C, Rumble JM, Oetjen KA, Wright CW, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Duckett CS. Cytoprotective effects of IAPs revealed by a small molecule antagonist. Biochem J. 2009 Feb 1;417(3):765-71. doi: 10.1042/BJ20081677. PMID: 18851715; PMCID: PMC2674510.
5: Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008 Jun 20;30(6):689-700. doi: 10.1016/j.molcel.2008.05.014. PMID: 18570872.
